Rubicon Research's record shows a company in transition: an IPO windfall of ₹471.27 crore (net of estimated IPO expense) arrived in FY26, yet free cash flow turned negative and a dividend was declared while the company consumed cash. Two things deserve attention: cumulative operating cash flow covers barely a third of cumulative EBITDA over seven years, and a performance undertaking for a subsidiary's factoring facility has more than doubled to 190.4 crore, shifting obligations off the balance sheet just as reported net debt moved to a net cash position.
Key findings
- IPO proceeds masked a sharp rise in factoring-linked obligations while reported debt fell
Major- The performance undertaking for step-down subsidiary AdvaGen Pharma Ltd's factoring arrangement rose to 190.4 crore as at 31 March 2026 from 78.74 crore a year earlier, with limits utilised of 186.85 crore. Over the same period, total borrowings fell from 393.17 crore to 259.37 crore and cash and equivalents rose, moving adjusted net debt from 353.03 crore to just 6.24 crore. The CFO stated on the Q4 FY26 call that the sequential increase in finance cost was "on account of our factoring, receivable factoring" and that "we factored one-third" of US receivables, without disclosing the absolute factoring amount or cost. - Revenue concentration is easing but remains deep, with five customers supplying 72% of revenue
Minor- Five customers each contributed 10% or more of consolidated revenue in FY26, together accounting for 72%, unchanged from FY25. On a standalone basis, the largest customer carried a year-end receivable of ₹583.88 crore, up from ₹372.1 crore. Trade receivables grew 57% year-on-year to ₹5,095.10 million while revenue grew 37%, though the impairment allowance remained low at ₹8.03 million. - Contingent tax demands in appeal rose 73%, and customs bonds rose 80%
Minor- The Group's contingent liabilities for income tax demands in appeal increased from 10.65 crore as at 31 March 2025 to 18.4 crore as at 31 March 2026. Customs bonds executed in favour of the Customs department under DGFT incentive schemes rose to 494.2 crore from 273.88 crore. On 5 January 2026, AdvaGen Pharma Ltd received a demand notice under section 156 of the Income-Tax Act from the Deputy Commissioner of Income Tax, Mumbai. - Promoter family holds interlocked board and management control, with a share in the investor's exit proceeds
Minor- Mrs. Pratibha Pilgaonkar, Managing Director, and Mr. Parag Sancheti, Executive Director & CEO, are related, he is her son-in-law, and together held 64,65,000 equity shares as of 31 March 2026. The Promote Agreement dated 30 July 2024 entitles the Pilgaonkar/Sancheti family to a portion of General Atlantic's cash consideration upon its exit, approved by public shareholders via postal ballot on 7 December 2025 with 88.81% votes in favour. The average annual increase in managerial remuneration was 37.28% in FY26, compared to 12.54% for employees excluding managerial personnel. - A FEMA compounding order was closed with penalty paid, and no capital-markets penalties were imposed
Clean- A compounding order under FEMA for delayed filing of Form ESOP was passed, the prescribed penalty was paid, and the matter stands closed. GST authorities conducted an inspection on 30 January 2026; no show-cause notice or order had been received as of the annual report date. No penalty or stricture was imposed by SEBI or Stock Exchanges in relation to any capital markets matter during FY26.
What to watch
- GST inspection outcome. The inspection conducted on 30 January 2026 had yielded no show-cause notice or order as of the FY26 annual report.
- KIA Health Tech merger. The scheme of merger is subject to member, Regional Director and regulatory approvals, with an appointed date of 1 April 2026.
- IPO proceeds utilisation. Deployment of the remaining net IPO proceeds against the stated objects, following significant capital deployed into investing activities in FY26.
Bottom line: This is a disclosed and audited record of a company that used its IPO proceeds to repay debt and fund expansion, but the cash generation behind the reported profit has been thin across the cycle. The risk sits in two places: the factoring arrangement that has shifted obligations off the balance sheet just as the company presents a net cash position, and the receivables book that is growing faster than revenue. Watch whether the GST inspection yields a notice, and track how the remaining IPO proceeds are deployed.